Background--Statins reduce aneurysm growth in mouse models of Marfan syndrome, although the mechanism is unknown. In addition to reducing cholesterol, statins block farnesylation and geranylgeranylation, which participate in membrane-bound G-protein signaling, including Ras. We dissected the prenylation pathway to define the effect of statins on aneurysm reduction.
treatment, several clinical trials have looked at the efficacy of various medical agents in slowing aneurysm growth, including b-blockers and angiotensin receptor blockers (losartan), whereas HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (statins) have been studied in animal models. 4, 5 Statins, a class of drugs originally utilized to reduce serum cholesterol, reduce aneurysm formation in a Marfan mouse model, although the mechanism remains unknown. 6 Statins have also been shown to reduce the ascending aortic aneurysm growth rate in humans, including in bicuspid aortic valveassociated aortopathies. 7, 8 Statins reduce cholesterol by inhibiting the enzyme HMG-CoA reductase, the rate-limiting step in the pathway that converts mevalonate to cholesterol. Statins exert other beneficial pleiotropic effects independent of their effects on cholesterol levels, including reduction in inflammation and MMP (matrix metalloproteinase) activity. [8] [9] [10] [11] Moreover, HMG-CoA reductase inhibition results in the decrease of the 15-and 20-carbon hydrocarbon chain isoprenoids, farnesyl and geranylgeranyl, respectively ( Figure 1 ). 12 Posttranslational modification of small guanine nucleotide-binding proteins (G-proteins), such as Ras and Rho, with isoprenoids is required for membrane localization. 12, 13 G-proteins are GTPases that cycle between active GTP-bound and inactive GDP-bound forms and are crucial for various cellular functions, including cell maintenance, motility, secretion, and proliferation. Membrane association allows the small G-proteins to associate with relevant membrane-bound proteins to permit downstream signaling. Ras-related proteins are typically farnesylated, whereas Rho proteins are geranylgeranylated. 13 In this study, by systemically dissecting the prenylation pathway, we sought (1) to compare the efficacy of HMG-CoA reductase inhibition and selective isoprenoid blockade on aneurysm prevention in an MFS mouse model, (2) to establish whether the beneficial effects of isoprenoid inhibition on aneurysm reduction can be attributed to alterations in small G-protein signaling in the aorta, and (3) to help further elucidate the role of TGF-b signaling during aneurysm formation. Identification of a more targeted pathway would provide a theoretical framework for the development of targeted therapeutics aimed at slowing aneurysm growth.
Methods
The data and analytic methods will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data will be maintained at the Stanford Thoracic Aortic Surgery Research Laboratory and available upon request. 
Experimental Animals

Clinical Perspective
What Is New?
• Using a murine model of Marfan syndrome, the novel findings from this study include the following: (1) Statins reduce aneurysm formation primarily via inhibition of Ras prenylation, (2) Ras prenylation reduction decreases downstream ERK (extracellular signal-regulated kinase) signaling, and (3) statin-mediated attenuation of Ras signaling correlates with inhibition of ERK-dependent MMP (matrix metalloproteinase) activation.
What Are the Clinical Implications?
• Although only prophylactic surgical replacement of the aortic root increases life expectancy in patients with Marfan syndrome, perhaps the optimal medical regimen to slow aneurysm growth or delay surgery should include drugs that block various locations within the TGF-b (transforming growth factor b) signaling pathway, including b-blockers, losartan, and statins. 
Animal Treatment Groups
Echocardiography
Transthoracic echocardiography was performed at age 4 weeks (baseline) and then at 6, 8, 10, and 12 weeks of age on mice sedated with 2% inhaled isoflurane (2-chloro-2-[difluoromethoxy]-1, 1, 1-trifluoro-ethane) delivered via nose cone. The aorta was imaged in the parasternal long-axis view using a Vevo-2100 echo (Visualsonics). The aortic diameter was measured 3 times (outer edge to outer edge) at the largest portion of the aortic root/ascending aorta by 2 blinded investigators. These 6 measurements were than averaged to represent the single data point for the animal. Statistical analysis was performed using the averaged measurements from different animals.
Histology
The ascending aorta was dissected and fixed in 4% paraformaldehyde. The aorta was embedded in Tissue-Tek OCT Compound Histomount (Sakura). The sample was sliced at 4-lm cross-sections and stained with the Accustain Elastin Verhoeff's Van Gieson kit (Sigma Aldrich), according to the manufacturer's instruction. The aorta was imaged at 940 magnification using a Leica DM4000B microscope. For quantification, the average number of elastin breaks per elastic lamina using the whole circumference was measured by a pathologist blinded to genotype and treatment arm. Three consecutive sections from each animal were graded and the average used for that individual animal was calculated. Statistical analysis was performed using the averaged measurements from 5 different animals.
Protein Assay
Protein from tissue or cells was extracted using radioimmunoprecipitation assay lysis buffer, and protein concentration was determined through a bicinchoninic acid assay, according to manufacturer's instructions (Thermo Scientific Pierce 
Smooth Muscle Cell Drug Treatment Studies, In Vitro
Aortic smooth muscle cells (SMCs) were derived from 4-weekold Fbn1 C1039G/+ and C57BL/6J WT littermate control mice.
SMCs were cultured in SMC media (SmGM-2 Bullet Kit; Lonza) and starved for 24 hours for the protein assay and for 48 hours for both the Ras activation and MMP (matrix metalloproteinase) activity assays. SMCs were treated with (4) vehicle control for 45 minutes, followed by mouse recombinant TGF-b (5 ng/mL). Experiments included 4 or 5 samples per group.
Ras Activation Assay, In Vitro
Ras activity was measured by the G-Lisa Ras Activation Assay Biochemistry kit (Cytoskeleton). Fbn1 C1039G/+ and WT SMCs were starved for 48 hours and then treated with mouse recombinant TGF-b (5 ng/lL) for 10 minutes. SMC protein was extracted using cell lysis buffer and immediately frozen in liquid nitrogen (stored at À80°C). Ras activity was measured according to the manufacturer's recommended protocol. Experiments included 4 or 5 samples per group.
MMP Activity Assay (Zymography)
In vitro , was added to 1 mL condition medium and incubated for 48 hours. Following drug treatment, SMC culture supernatants were collected and concentrated using Amicon Ultra-4 centrifugal filters (Ultracel-30K; MilliporeSigma). MMP zymography assays were performed using the Gelatin-Zymography kit (Cosmo Bio). Concentrated supernatant (10 lL) was placed into each well and MMP2 activity was measured, according to the manufacturer's instructions. Experiments included 5 samples per group.
In vivo
Fbn1 C1039G/+ mice (4 weeks old) were treated with either (1) pravastatin or (2) vehicle control from ages 4 to 8 weeks. Animals were euthanized at age 12 weeks (n=5 per group). The aortic root/ascending aortas were harvested and protein collected. MMP zymography assays were performed using the Gelatin-Zymography Kit, as noted. Protein samples (6 lg) were placed into each well, and MMP2 activity was measured according to the manufacturer's instructions. MMP2 activity levels were compared with MMP2 markers and then expressed as fold difference versus littermate WT control mice.
Statistical Analysis
Statistical analysis was performed using SPSS 119.0 (IBM Corp). Data are presented as meanAESD. When comparing aortic diameter growth pattern between treatment groups, a linear mixed effects model was used. The Mann-Whitney and Kruskal-Wallis nonparametric tests were used to compare non-normally distributed data, with data expressed as median and interquartile range. Significance of individual differences was evaluated using the Bonferroni or Steel-Dwann correction for multiple comparisons. A value of P<0.05 was considered statistically significant. ( Figure 6 , n=5 per group).
Results
Effect of Prenylation Inhibitors on Aneurysm Formation in Marfan Mice
1.56AE0.03 mm, P=0.003). To better define the role of specific isoprenoids in statin-induced Marfan aneurysm reduction
Discussion
The pathophysiology of aneurysm formation in MFS is a complex multifactorial process involving vascular SMC apoptosis, reduced elastin production and stability, and enhanced extracellular matrix breakdown and remodeling. [14] [15] [16] Understanding the molecular pathways that lead to aneurysm formation may translate into novel medical therapies directed at preventing or slowing aneurysm growth. Statins (HMG-CoA reductase inhibitors) are lipid-lowering agents that have beneficial pleiotropic, cholesterol-independent protective effects, including anti-inflammatory, antioxidative, and antiproliferative properties. [8] [9] [10] [11] Utilizing HMG-CoA reductase and selective isoprenoid inhibitors, we have systematically dissected the prenylation pathway to better define the mechanism behind statin reduction of aneurysm formation in a murine model of MFS (Figures 1 and 7) . The major findings of this study are as follows: (1) Statins reduce aneurysm formation primarily via inhibition of Ras prenylation, (2) Ras prenylation reduction decreases downstream ERK signaling, and (3) statin-mediated attenuation of Ras signaling correlates with inhibition of ERK-dependent MMP activation.
In the current study, we use a well-established Marfan mouse model that reproducibly develops ascending aortic aneurysms, recapitulating the pathology seen in human MFS. The Fbn1 mutation in this model system leads to enhanced TGF-b signaling, acting predominantly via the noncanonical ERK pathway. 2, 17 Importantly, the molecular mechanisms by which excessive ERK signaling leads to aneurysm development remain unknown. In this study, we further delineated the pathway of ERK-mediated aneurysm formation in this model system, reporting that Ras-dependent ERK activation increases MMP activation. Statins have previously been proposed to slow abdominal aortic aneurysm growth, given their pleiotropic, anti-inflammatory actions rather than their lipid-lowering effects. 18, 19 Several previous studies have reported that inflammatory cells are major sources of MMPs during abdominal aortic aneurysm formation in both human and animal models of abdominal aortic aneurysm formation. 20, 21 Importantly, the absence of inflammatory cells in this Marfan model suggests that statins must reduce aneurysm formation through an alternative mechanism, likely via the diminution of MMPs or other yet unmeasured elastases produced directly from SMCs. Nevertheless, we cannot rule out the possibility that statins enhance SMC survival and elastin production. Prenylation inhibitors are utilized as a tool to further delineate the mechanism leading to TGF-b-mediated aneurysm formation in the and (3) the MMP activity assay has limitations. Ras proteins are small GTPases that translocate from the cytoplasm to the plasma membrane following farnesylation by farnesyltransferase-essential for turning on downstream signaling pathways, including ERK-and then activate transcription factors. 22, 23 Analyzing the prenylation pathway, MA seems to be most effective at reducing aneurysm formation because it blocks farnesyltransferase (N-Ras, K-Ras). In contrast, we hypothesize that PA, which predominantly inhibits geranylgeranyl transferase 1 and 2 and, to a smaller extent, farnesyltransferase, is less effective at reducing aneurysm formation because it blocks the GTPases Rap and Rab and, to a minor extent, Ras. 24 An obvious study limitation is that the individual GTPases were not quantified; therefore, we cannot comment on the relative amounts that each were reduced.
Using the same mouse model, McLoughlin et al initially described the attenuation of aortic dilatation by pravastatin but attributed the reduction to a yet undefined decreased in protein production because they noted reduced rough endoplasmic reticulum histologically. 6 Supporting our findings, Luan et al found that statins can inhibit vascular SMC secretion of MMP1, -2, -3, and -9 in vitro given an indeterminate posttranscriptional process. 9 Approaches to target and inhibit Ras proteins are under way in many biotechnology and pharmaceutical companies, especially in the area of human cancers, RASopathies (neurofibromatosis type 1, Noonan syndrome, Noonan with Multiple Lentigines [NSML], Cardio-Facio-Cutaneous (CFC), and Costello and Legius syndromes), and neurological disorders. [25] [26] [27] [28] There are challenges to blocking Ras signaling, including its physical structure, multiple feedback loops and signaling redundancy, and the fact it is a critical pathway for most normal cells. Statin therapy may be an innocuous strategy to reduce TGF-bmediated Ras/ERK activation in Marfan patients, without the potentially harmful systemic affects (immunity and cell growth). 4, 6, 29 Notably, although excessive TGF-b signaling In Fbn1 C1039G/+ aortic root/ascending aorta, we hypothesize that TGF-b activates Ras, which triggers ERK signaling. ERK activation regulates a wide variety of targets involved in breakdown of the extracellular matrix (ECM), including the matrix metalloproteinases (MMPs). We believe statins indirectly reduce TGF-b-dependent ERK activation by preventing Ras modification with isoprenoids, thereby decreasing membrane association. HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; MA, manumycin A; PA, perillyl alcohol; pERK, phosphorylated ERK; pRaf1, phosphorylated c-Raf; STATIN, pravastatin; Tip, tipifarnib.
promotes aneurysm formation by increasing ERK activation in mice, whether this mechanism has fidelity with the human disease has not been firmly established. Furthermore, because TGF-b stimulates multiple signaling pathways, it is unclear which pathways result in aortic disease. Although only prophylactic surgical replacement of the aortic root effectively increases life expectancy in MFS patients, perhaps the optimal medical regimen to slow aneurysm growth or delay surgery should include drugs that block various locations within the TGF-b signaling pathway, including b-blockers, losartan, and statins. The answer is most likely to be found only with a large prospective randomized clinical trial.
